series-a
Stage
1
Investors
About
Syntis develops oral therapies leveraging the small intestine's biology to treat obesity, rare genetic disorders, and other related diseases by advancing a pipeline of drug candidates.
Explore Syntis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.